Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Net Cash Flow: 2020-2025

Historic Net Cash Flow for Tango Therapeutics (TNGX) over the last 6 years, with Sep 2025 value amounting to $19.1 million.

  • Tango Therapeutics' Net Cash Flow rose 1105.18% to $19.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year increase of 183.16%. This contributed to the annual value of $2.3 million for FY2024, which is 60.87% down from last year.
  • Per Tango Therapeutics' latest filing, its Net Cash Flow stood at $19.1 million for Q3 2025, which was up 199.51% from -$19.2 million recorded in Q2 2025.
  • Tango Therapeutics' 5-year Net Cash Flow high stood at $154.1 million for Q3 2021, and its period low was -$62.2 million during Q4 2021.
  • For the 3-year period, Tango Therapeutics' Net Cash Flow averaged around -$277,545, with its median value being -$3.3 million (2023).
  • Within the past 5 years, the most significant YoY rise in Tango Therapeutics' Net Cash Flow was 9,825.87% (2021), while the steepest drop was 59,672.68% (2021).
  • Tango Therapeutics' Net Cash Flow (Quarterly) stood at -$62.2 million in 2021, then spiked by 35.17% to -$40.3 million in 2022, then soared by 119.46% to $7.9 million in 2023, then soared by 108.63% to $16.4 million in 2024, then surged by 1,105.18% to $19.1 million in 2025.
  • Its Net Cash Flow was $19.1 million in Q3 2025, compared to -$19.2 million in Q2 2025 and -$11.1 million in Q1 2025.